351 related articles for article (PubMed ID: 35176098)
21. Semaphorin 7A in circulating regulatory T cells is increased in autosomal-dominant polycystic kidney disease and decreases with tolvaptan treatment.
Lee Y; Blount KL; Dai F; Thompson S; Scher JK; Bitterman S; Droher M; Herzog EL; Moeckel G; Karihaloo A; Dahl NK
Clin Exp Nephrol; 2018 Aug; 22(4):906-916. PubMed ID: 29453607
[TBL] [Abstract][Full Text] [Related]
22. Long-term effectiveness and safety of tolvaptan in autosomal dominant polycystic kidney disease.
Cantarelli L; Gutiérrez Valencia M; Leache Alegria L; Sainz Fernandez LC; Erviti Lopez J; Gutiérrez Nicolas F; Nazco Casariego GJ
Med Clin (Barc); 2024 Jul; 163(1):1-7. PubMed ID: 38616432
[TBL] [Abstract][Full Text] [Related]
23. Urinary EGF Receptor Ligand Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease and Response to Tolvaptan.
Harskamp LR; Gansevoort RT; Boertien WE; van Oeveren W; Engels GE; van Goor H; Meijer E
Clin J Am Soc Nephrol; 2015 Oct; 10(10):1749-56. PubMed ID: 26231191
[TBL] [Abstract][Full Text] [Related]
24. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.
van Aerts RMM; Kievit W; D'Agnolo HMA; Blijdorp CJ; Casteleijn NF; Dekker SEI; de Fijter JW; van Gastel M; Gevers TJ; van de Laarschot LFM; Lantinga MA; Losekoot M; Meijer E; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Visser FW; Wetzels JF; Zietse R; Gansevoort RT; Drenth JPH;
Gastroenterology; 2019 Aug; 157(2):481-491.e7. PubMed ID: 31022403
[TBL] [Abstract][Full Text] [Related]
25. Tolvaptan in patients with autosomal dominant polycystic kidney disease.
Torres VE; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang J; Czerwiec FS;
N Engl J Med; 2012 Dec; 367(25):2407-18. PubMed ID: 23121377
[TBL] [Abstract][Full Text] [Related]
26. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
Bennett H; McEwan P; Hamilton K; O'Reilly K
BMC Nephrol; 2019 Apr; 20(1):136. PubMed ID: 31014270
[TBL] [Abstract][Full Text] [Related]
27. An update on tolvaptan for autosomal dominant polycystic kidney disease.
Poch E; Rodas L; Blasco M; Molina A; Quintana L
Drugs Today (Barc); 2018 Sep; 54(9):519-533. PubMed ID: 30303493
[TBL] [Abstract][Full Text] [Related]
28. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.
Gansevoort RT; van Gastel MDA; Chapman AB; Blais JD; Czerwiec FS; Higashihara E; Lee J; Ouyang J; Perrone RD; Stade K; Torres VE; Devuyst O;
Kidney Int; 2019 Jul; 96(1):159-169. PubMed ID: 30898339
[TBL] [Abstract][Full Text] [Related]
29. Public support for patients with intractable diseases in Japan: impact on clinical indicators from nationwide registries in patients with autosomal dominant polycystic kidney disease.
Kataoka H; Shimada Y; Kimura T; Nishio S; Nakatani S; Mochizuki T; Tsuchiya K; Hoshino J; Hattanda F; Kawano H; Hanaoka K; Hidaka S; Ichikawa D; Ishikawa E; Uchiyama K; Hayashi H; Makabe S; Manabe S; Mitobe M; Sekine A; Suwabe T; Kai H; Kurashige M; Seta K; Shimazu K; Moriyama T; Sato M; Otsuka T; Katayama K; Shimabukuro W; Fujimaru T; Miura K; Nakanishi K; Horie S; Furuichi K; Okada H; Narita I; Muto S
Clin Exp Nephrol; 2023 Oct; 27(10):809-818. PubMed ID: 37368094
[TBL] [Abstract][Full Text] [Related]
30. Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials.
Alpers DH; Lewis JH; Hunt CM; Freston JW; Torres VE; Li H; Wang W; Hoke ME; Roth SE; Westcott-Baker L; Estilo A
Am J Kidney Dis; 2023 Mar; 81(3):281-293.e1. PubMed ID: 36191725
[TBL] [Abstract][Full Text] [Related]
31. Assessing Risk of Rapid Progression in Autosomal Dominant Polycystic Kidney Disease and Special Considerations for Disease-Modifying Therapy.
Chebib FT; Torres VE
Am J Kidney Dis; 2021 Aug; 78(2):282-292. PubMed ID: 33705818
[TBL] [Abstract][Full Text] [Related]
32. Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?
Janssens P; Weydert C; De Rechter S; Wissing KM; Liebau MC; Mekahli D
Pediatr Nephrol; 2018 Mar; 33(3):395-408. PubMed ID: 28455745
[TBL] [Abstract][Full Text] [Related]
33. Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
Torres VE; Chapman AB; Devuyst O; Gansevoort RT; Perrone RD; Koch G; Ouyang J; McQuade RD; Blais JD; Czerwiec FS; Sergeyeva O;
N Engl J Med; 2017 Nov; 377(20):1930-1942. PubMed ID: 29105594
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the Renal and Cardiovascular Effects of Long-Term Tolvaptan Treatment in Autosomal Dominant Polycystic Kidney Disease.
Demiray A; Ozan R; Özaytürk SG; İmamoğlu H; Zararsız G; Sipahioğlu MH; Tokgöz B; Elçik D; Koçyiğit İ
Cardiorenal Med; 2024; 14(1):167-177. PubMed ID: 38423003
[TBL] [Abstract][Full Text] [Related]
35. Initial decline in eGFR to predict tolvaptan response in autosomal-dominant polycystic kidney disease.
Akihisa T; Kataoka H; Makabe S; Manabe S; Yoshida R; Ushio Y; Sato M; Tsuchiya K; Mochizuki T; Nitta K
Clin Exp Nephrol; 2022 Jun; 26(6):540-551. PubMed ID: 35165806
[TBL] [Abstract][Full Text] [Related]
36. A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.
Chebib FT; Perrone RD; Chapman AB; Dahl NK; Harris PC; Mrug M; Mustafa RA; Rastogi A; Watnick T; Yu ASL; Torres VE
J Am Soc Nephrol; 2018 Oct; 29(10):2458-2470. PubMed ID: 30228150
[TBL] [Abstract][Full Text] [Related]
37. Tolvaptan promotes urinary excretion of sodium and urea: a retrospective cohort study.
Minami S; Hamano T; Iwatani H; Mizui M; Kimura Y; Isaka Y
Clin Exp Nephrol; 2018 Jun; 22(3):550-561. PubMed ID: 29052786
[TBL] [Abstract][Full Text] [Related]
38. Pro: Tolvaptan delays the progression of autosomal dominant polycystic kidney disease.
Torres VE
Nephrol Dial Transplant; 2019 Jan; 34(1):30-34. PubMed ID: 30312438
[TBL] [Abstract][Full Text] [Related]
39. Tolvaptan vs. somatostatin in the treatment of ADPKD: A review of the literature.
Capuano I; Buonanno P; Riccio E; Rizzo M; Pisani A
Clin Nephrol; 2022 Mar; 97(3):131-140. PubMed ID: 34846296
[TBL] [Abstract][Full Text] [Related]
40. Persistence of tolvaptan medication for autosomal dominant polycystic kidney disease: A retrospective cohort study using Shizuoka Kokuho Database.
Saito R; Yamamoto H; Ichihara N; Kumamaru H; Nishimura S; Shimada K; Mori K; Miyachi Y; Miyata H
Medicine (Baltimore); 2022 Oct; 101(40):e30923. PubMed ID: 36221375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
